AbbVie reports AFFIRM data; stock pre-market at EUR 245.50
Published on 10/14/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data and outlook
- AbbVie announced new AFFIRM findings on October 13, 2026.
- AbbVie stock trades pre-market at EUR 245.50 at 7:38 a.m. CEST at Lang & Schwarz on October 14, 2026.
- The Phase 3 study randomized 289 patients in a 2:1 ratio to SKYRIZI or placebo.
AbbVie reported new Phase 3 AFFIRM findings on October 13, 2026, while its stock traded pre-market at EUR 245.50 at 7:38 a.m. CEST on October 14, 2026, according to Lang & Schwarz.
Pre-market trading
The Lang & Schwarz price was EUR 245.50 on October 14, 2026, at 7:38 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
What matters today. The next company date identified for AbbVie is October 30, 2026, when the company is scheduled to report third-quarter results before the market opens. EUR 250.00 is 1.83 percent above the pre-market price of EUR 245.50. The AFFIRM study randomized 289 patients in a 2:1 ratio to subcutaneous SKYRIZI or placebo.
AFFIRM study findings
In the release distributed by PR Newswire, AbbVie said 35.8 percent of patients receiving subcutaneous SKYRIZI achieved endoscopic remission at week 24, compared with 9.1 percent on placebo. Ulcer-free endoscopy was reached by 36.6 percent of SKYRIZI patients and 9.1 percent of placebo patients.
The subcutaneous induction regimen is under review by the U.S. Food and Drug Administration and the European Medicines Agency. AbbVie said safety findings through week 24 were consistent with risankizumab’s known safety profile and that no new safety signals were identified.
Market context: Market report S&P 500.
